Form 8-K - Current report:
SEC Accession No. 0001999371-24-011157
Filing Date
2024-08-30
Accepted
2024-08-30 17:08:17
Documents
15
Period of Report
2024-08-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp_8k-083024.htm   iXBRL 8-K 24999
2 OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP ex5-01.htm EX-5.01 12722
3 GRAPHIC ex5-01_img001.gif GRAPHIC 1942
  Complete submission text file 0001999371-24-011157.txt   216754

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tnxp-20240830.xsd EX-101.SCH 3024
5 XBRL LABEL FILE tnxp-20240830_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE tnxp-20240830_pre.xml EX-101.PRE 22365
17 EXTRACTED XBRL INSTANCE DOCUMENT tnxp_8k-083024_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 241271003
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)